United States Patent 8,093,423: Analysis of Scope, Claims, and Landscape
United States Patent 8,093,423, titled "Methods of administering and treating therewith," was granted to Merck & Co., Inc. on January 10, 2012. The patent covers methods for treating or preventing a disease in a subject by administering a specific compound. The primary focus is on the administration of Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor used in the treatment of type 2 diabetes. The patent's claims define specific dosages and administration regimens for Sitagliptin, aiming to establish a protected method of use for the drug.
What is the Core Invention of Patent 8,093,423?
The central invention protected by US Patent 8,093,423 is a method of treating or preventing a disease in a subject. Specifically, the method involves administering a therapeutic compound, identified as Sitagliptin, in a precise dosage and regimen. The patent claims define the use of Sitagliptin in dosages ranging from 50 mg to 100 mg daily. This focus on specific administration parameters aims to carve out protection for a particular therapeutic application of the known compound.
What are the Key Claims of Patent 8,093,423?
Patent 8,093,423 includes several independent and dependent claims that define the scope of the protected invention. These claims are critical for understanding the boundaries of Merck & Co., Inc.'s exclusive rights.
Claim 1: The Foundational Method Claim
The broadest independent claim, Claim 1, defines the core method. It asserts:
"A method of treating or preventing a disease in a subject which comprises administering to a subject a therapeutically effective amount of a compound of Formula I:
[Chemical structure of Sitagliptin]
or a pharmaceutically acceptable salt thereof, wherein the compound is administered in an amount of from about 50 mg to about 100 mg per day."
This claim establishes the compound (Sitagliptin) and a defined daily dosage range as the basis for the protected method.
Dependent Claims: Refining the Method
Dependent claims further refine the method described in Claim 1, adding specific details and limitations. Examples include:
- Claim 2: Specifies administering the compound in an amount of about 100 mg per day.
- Claim 3: Specifies administering the compound in an amount of about 50 mg per day.
- Claim 4: Specifies administering the compound once daily.
- Claim 5: Relates to the compound being in the form of a phosphate salt.
- Claim 6: Focuses on the disease being type 2 diabetes.
- Claim 7: Relates to the subject being a mammal.
These dependent claims narrow the scope of the invention, offering layered protection for specific administration protocols and patient populations.
What is the Technology Covered by Patent 8,093,423?
The technology described in Patent 8,093,423 centers on the pharmacological application of Sitagliptin. Sitagliptin is a well-established selective inhibitor of dipeptidyl peptidase-4 (DPP-4). DPP-4 is an enzyme that inactivates incretin hormones, which play a role in glucose regulation. By inhibiting DPP-4, Sitagliptin increases the levels of active incretin hormones (GLP-1 and GIP), thereby enhancing insulin secretion and suppressing glucagon release in a glucose-dependent manner. This mechanism leads to improved glycemic control in patients with type 2 diabetes.
The patent's claims are directed towards the method of using Sitagliptin, rather than the compound itself or its initial synthesis. This signifies a focus on a specific therapeutic application and dosage regimen.
Who is the Patent Holder and What is Its Significance?
The patent holder is Merck & Co., Inc. (known as MSD outside the United States and Canada). Merck is a global pharmaceutical company with a significant portfolio of drugs, including several in the diabetes care space. The granting of Patent 8,093,423 to Merck underscores its established position in the development and commercialization of diabetes treatments.
The significance of this patent lies in its potential to extend market exclusivity for Sitagliptin-based therapies, particularly if it survived potential challenges to its validity or inventiveness. For competitors seeking to market generic versions of Sitagliptin, this patent represents a hurdle that must be navigated.
What is the Current Patent Landscape for Sitagliptin and Related Therapies?
The patent landscape surrounding Sitagliptin is complex and involves multiple patents covering various aspects of the drug, including its composition, synthesis, polymorphs, formulations, and methods of use.
Key Patents and Their Focus:
- Composition of Matter Patents: These are typically the earliest and strongest patents, covering the Sitagliptin molecule itself. For example, US Patent 6,699,861, also held by Merck, covers Sitagliptin and related compounds.
- Formulation Patents: These patents protect specific ways the drug is prepared for administration, such as specific tablet formulations, controlled-release mechanisms, or combinations with other active ingredients.
- Process Patents: These cover specific methods for synthesizing Sitagliptin.
- Method of Use Patents: This is where Patent 8,093,423 falls. It protects specific ways of using the drug to treat a disease.
The Role of Patent 8,093,423 in the Landscape:
Patent 8,093,423, by focusing on a specific daily dosage range (50-100 mg) and daily administration for treating type 2 diabetes, aims to provide a distinct layer of protection beyond the original composition of matter patents. Such method-of-use patents can be crucial for extending the commercial life of a drug by preventing generic manufacturers from marketing the drug for the patented indication and dosage, even if the composition of matter patent has expired.
Generic manufacturers often target patents that are perceived as weaker or have narrower scope. Method-of-use patents, while valuable, can sometimes be more susceptible to challenges if the claimed method is considered obvious in light of prior art or if the claimed dosage regimen does not provide a significant, unexpected therapeutic benefit over existing methods.
Litigation and Challenges:
Sitagliptin, like many blockbuster drugs, has been subject to patent litigation. Generic companies have sought to invalidate Merck's patents or design around them. The specific claims of Patent 8,093,423 would have been assessed in any such legal proceedings concerning the broader Sitagliptin patent estate. Challenges often focus on:
- Obviousness: Whether the claimed invention would have been obvious to a person skilled in the art at the time of filing.
- Novelty: Whether the claimed invention was previously known or described in the prior art.
- Enablement and Written Description: Whether the patent adequately describes the invention and enables someone skilled in the art to practice it.
The existence and strength of Patent 8,093,423 would have influenced the strategies of generic manufacturers looking to enter the market with Sitagliptin products.
What is the Geographic Scope of Patent 8,093,423?
Patent 8,093,423 is a United States patent. Its protection is therefore limited to the territory of the United States of America. This means that Merck & Co., Inc. has exclusive rights to practice the claimed methods within the U.S. for the term of the patent.
What is the Term of Patent 8,093,423?
United States patents generally have a term of 20 years from the date of filing, subject to payment of maintenance fees. Patent 8,093,423 was filed on November 3, 2004, and granted on January 10, 2012. Therefore, its term would have been calculated from the filing date. Assuming full maintenance fees were paid, the patent would have expired on November 3, 2024.
- Filing Date: November 3, 2004
- Grant Date: January 10, 2012
- Estimated Expiration Date: November 3, 2024 (20 years from filing date, assuming no patent term extensions)
It is important to note that patent term extensions (PTEs) can be granted to compensate for certain delays in patent prosecution or regulatory review, which could extend the effective term of the patent. The actual expiration date would need to be verified through official U.S. Patent and Trademark Office (USPTO) records.
What are the Implications for Generic Competition?
The expiration of Patent 8,093,423, along with other key Sitagliptin patents, opens the door for generic competition within the United States. Generic drug manufacturers can now legally market their own versions of Sitagliptin for the treatment of type 2 diabetes, provided they have obtained FDA approval for their Abbreviated New Drug Application (ANDA) and are not infringing on any remaining valid patents.
Key Considerations for Generic Entry:
- Patent Expiration: The expiry of this method-of-use patent (and others like it) is a primary trigger for generic market entry.
- FDA Approval: Generic manufacturers must demonstrate bioequivalence to the reference listed drug (Januvia, the brand name for Sitagliptin) and meet other FDA requirements.
- Remaining Patents: While Patent 8,093,423 may have expired, it is crucial for generic companies to analyze the entire Sitagliptin patent landscape to ensure no other active patents are being infringed. This includes patents on formulations, manufacturing processes, or combination therapies.
- Market Dynamics: The entry of generics typically leads to significant price reductions for the drug, impacting revenue for the innovator company and creating cost-saving opportunities for healthcare providers and patients.
For Merck, the expiration of this patent signifies the end of specific patent-protected market exclusivity for this method of administering Sitagliptin in the U.S.
How Does Patent 8,093,423 Compare to Other Sitagliptin Patents?
Patent 8,093,423 is a method-of-use patent, distinct from earlier and potentially broader composition-of-matter patents.
- Composition of Matter Patents (e.g., US 6,699,861): These patents protect the Sitagliptin molecule itself. They are typically filed early in the drug development process and provide the most fundamental protection. These patents have generally expired or are close to expiring, allowing for generic entry based on the molecule itself.
- Formulation Patents: These protect specific delivery systems or physical forms of the drug. These can extend market exclusivity beyond the composition of matter patent expiration if they cover a significant improvement or a unique aspect of the drug product.
- Method of Use Patents (e.g., US 8,093,423): These patents protect a specific application of a known compound. They are often filed later and can be used to extend exclusivity for particular therapeutic indications or dosage regimens. Their strength can depend on demonstrating a new and non-obvious use or a significant therapeutic advantage.
Patent 8,093,423's focus on the 50-100 mg daily dosage for type 2 diabetes represents a specific aspect of Sitagliptin's therapeutic profile. Its value lies in its ability to prevent competitors from marketing the drug specifically for this defined regimen, even if they have access to the Sitagliptin molecule itself due to the expiration of earlier patents. However, its narrower scope compared to composition patents means it may have less impact on broad generic entry once the fundamental patents expire.
What is the Commercial Context of Patent 8,093,423?
Patent 8,093,423 was filed by Merck & Co., Inc., the innovator of Sitagliptin, marketed under the brand name Januvia. Januvia was first approved by the FDA in 2006 and quickly became a blockbuster drug for the treatment of type 2 diabetes.
The commercial significance of this patent lies in its role within Merck's broader patent strategy to protect its investment in Januvia. By securing method-of-use patents like 8,093,423, Merck aimed to:
- Extend Market Exclusivity: Prevent generic competitors from marketing Sitagliptin for the specifically claimed dosages and indications, even after the primary composition patents expired.
- Maintain Pricing Power: Continue to command premium pricing for Januvia by limiting the competitive landscape.
- Protect Market Share: Safeguard its significant market share in the highly competitive diabetes drug market.
The commercial impact of this patent would have been most pronounced in the period leading up to its expiration, potentially delaying or restricting the market entry of generic Sitagliptin at specific dosage regimens.
Key Takeaways
- US Patent 8,093,423, granted to Merck & Co., Inc. on January 10, 2012, protects methods of treating or preventing disease by administering Sitagliptin in daily dosages of approximately 50 mg to 100 mg.
- The patent's claims are specifically directed towards a method of use, defining a particular therapeutic regimen for Sitagliptin, a DPP-4 inhibitor for type 2 diabetes.
- The patent holder is Merck & Co., Inc., the innovator of the drug Januvia.
- The patent's geographic scope is limited to the United States.
- The patent's term is 20 years from its filing date of November 3, 2004, likely expiring around November 3, 2024, subject to potential extensions.
- This method-of-use patent is part of a larger patent estate for Sitagliptin, complementing composition of matter and formulation patents.
- The expiration of this patent facilitates generic competition for Sitagliptin at the claimed dosage regimens in the U.S. market.
Frequently Asked Questions
-
What is the primary therapeutic indication covered by Patent 8,093,423?
The primary therapeutic indication covered by Patent 8,093,423 is the treatment of type 2 diabetes.
-
Does Patent 8,093,423 cover the Sitagliptin molecule itself?
No, Patent 8,093,423 does not cover the Sitagliptin molecule itself. It is a method-of-use patent that claims specific ways of administering the compound.
-
What is the specific dosage range claimed in Patent 8,093,423?
The patent claims the administration of Sitagliptin in an amount of approximately 50 mg to 100 mg per day.
-
What is the expiration date of United States Patent 8,093,423?
The patent was filed on November 3, 2004, and has a term of 20 years from the filing date, making its likely expiration around November 3, 2024, assuming no patent term extensions.
-
Can generic versions of Sitagliptin be sold in the U.S. now that this patent has expired?
The expiration of this patent removes one layer of protection for the method of use described. However, generic entry also depends on the expiration of other Sitagliptin patents (e.g., composition of matter, formulation) and obtaining FDA approval for generic versions.
Citations
[1] Merck & Co., Inc. (2012). U.S. Patent No. 8,093,423. Washington, DC: U.S. Patent and Trademark Office.
[2] U.S. Food & Drug Administration. (n.d.). Drug Approval Packages - Januvia. Retrieved from [relevant FDA portal, if publicly accessible and searchable for specific approval details]
[3] Merck & Co., Inc. (2004). U.S. Patent No. 6,699,861. Washington, DC: U.S. Patent and Trademark Office.
